---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-024697"
form_type: "8-K"
ticker: "SIGA"
cik: "0001010086"
company_name: "SIGA TECHNOLOGIES INC"
filed_at: "2024-05-07T23:59:59+00:00"
generated_at: "2026-06-02T15:19:43.945112+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SIGA Q1 2024: product sales $23.9M, net income $10.3M, $0.60 special dividend

## Summary
- Product sales $23.9M vs $5.7M YoY; total revenues $25.4M vs $8.3M.
- Operating income $11.3M vs loss $2.1M YoY; net income $10.3M vs loss $0.9M; diluted EPS $0.14 vs ($0.01).
- Partner Japan Biotechno Pharma filed NDA for tecovirimat in Japan for smallpox, mpox, etc. on April 11, 2024.
- Amendment to Meridian agreement: SIGA takes over international promotion of oral TPOXX effective June 1, 2024.
- Special cash dividend of $0.60 per share declared March 12, paid April 11, 2024.

## SEC filing metadata
- accession: 0001140361-24-024697
- form_type: 8-K
- ticker: SIGA
- cik: 0001010086
- company_name: SIGA TECHNOLOGIES INC
- filed_at: 2024-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1010086/000114036124024697/0001140361-24-024697-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1010086/000114036124024697/ef20028413_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-024697
- JSON: https://secwatch.observer/filing/0001140361-24-024697.json
- Plain text: https://secwatch.observer/filing/0001140361-24-024697.txt

## Key facts
- Earnings Releases
  SIGA TECHNOLOGIES INC reported three months ended March 31, 2024 results: revenue $ 25.4, net income $ 10.3, EPS $ 0.14.
  - Period: three months ended March 31, 2024
  - Revenue: $ 25.4
  - Net income: $ 10.3
  - EPS: $ 0.14
  - Result: reported results
  source text: Summary Financial Results ($ in millions, except per share amounts) Three Months Ended March 31 2024 2023 Product sales (1) $ 23.9 $ 5.7 Total revenues $ 25.4 $ 8.3 Operating income (loss) (2) $ 11.3 $ (2.1 ) Income (loss) before income taxes (2) $ 13.2 $ (1.2 ) Net income (loss) $ 10.3 $ (0.9 ) Diluted income (loss) per share $ 0.14 $ (0.01 )
  evidence_url: https://www.sec.gov/Archives/edgar/data/1010086/000114036124024697/0001140361-24-024697-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.